Related Experiment Video
Updated: Aug 10, 2026
Detection of CD40 Protein-Umbelliferone Interaction via Differential Scanning Fluorescence
Published on: March 1, 2024
Influence of sample type and storage conditions on soluble CD40 ligand assessment
Michael Weber1, Birgitt Rabenau, Michael Stanisch
1Kerckhoff Heart Center, Department of Cardiology, Bad Nauheim, Germany. M.Weber@kerckhoff-klinik.de
Insights
Accurate measurement of soluble CD40 ligand (sCD40L) requires careful attention to preanalytic conditions. Plasma samples are recommended over serum for reliable sCD40L assessment in cardiovascular studies.
Area of Science:
- Cardiovascular Medicine
- Biomarker Research
- Clinical Chemistry
Background:
- Soluble CD40 ligand (sCD40L) is elevated in acute coronary syndromes and serves as a risk stratification biomarker.
- Limited data exist on preanalytic variables affecting sCD40L measurements.
Purpose of the Study:
- To investigate the impact of different blood sampling techniques and storage conditions on sCD40L concentrations.
Main Methods:
- Prospective study involving 30 patients with coronary heart disease (no, stable, or unstable).
- Blood samples collected in gel tubes, EDTA tubes, and citrate tubes.
- Evaluated various storage conditions and processing times.
Main Results:
- Serum sCD40L levels were significantly higher than EDTA or citrate plasma levels at baseline.
- Serum sCD40L increased with delayed processing, while plasma levels remained stable post-centrifugation.
- sCD40L concentrations were stable across all sample types after centrifugation.
Conclusions:
- Plasma samples (EDTA or citrate) are suitable for sCD40L measurement, unlike serum.
- Preanalytic factors critically influence sCD40L assessment and must be standardized for future research.
Background:
Several studies have consistently shown that soluble CD40 ligand (sCD40L) concentrations are increased in patients with acute coronary syndromes and can serve as a biomarker for risk stratification. However, few data are available on preanalytic conditions that impact sCD40L values. Thus, the aim of our prospective study was to evaluate the impact of sampling techniques and storage conditions on sCD40L concentrations.
Methods:
We included a total of 30 patients with no, stable, or unstable coronary heart disease. Blood samples were collected in gel-filled tubes without additives, in EDTA-filled tubes, and in citrate-filled tubes and were kept at various storage conditions.
Results:
Median (interquartile range) sCD40L values at baseline were higher in serum samples [5.29 (3.89-6.33) microg/L] than in either EDTA plasma [0.78 (0.39-1.12) microg/L; P <0.001] or citrate plasma [0.37 (0.22-0.51) microg/L; P <0.001]. Serum values increased with delayed processing [7.94 (5.97-9.62) microg/L after 1.5 h (P <0.001) vs baseline; 10.55 (7.58-11.55) microg/L after 3 h (P <0.001) vs baseline]. However, after centrifugation, sCD40L values remained stable for all 3 sample types.
Conclusion:
Plasma, but not serum, samples are appropriate for sCD40L measurements. In general, preanalytic conditions are critical in the assessment of sCD40L concentrations and thus should be carefully considered for future studies.
